<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19296">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855684</url>
  </required_header>
  <id_info>
    <org_study_id>EFC12814</org_study_id>
    <secondary_id>U1111-1139-3894</secondary_id>
    <nct_id>NCT02855684</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy</brief_title>
  <acronym>EDITION AP</acronym>
  <official_title>6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the efficacy of insulin glargine (U300) and Lantus in terms of change of glycated
      hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled at Month 6, Week 26) in patients
      with type 2 diabetes mellitus.

      Secondary Objectives:

        -  To compare insulin glargine (U300) and Lantus in terms of occurrence of hypoglycemia
           and nocturnal hypoglycemia.

        -  To compare insulin glargine (U300) and Lantus in terms of reaching target HbA1c values
           (all and reaching target without hypoglycemia).

        -  To compare insulin glargine (U300) and Lantus in terms of controlled plasma glucose
           (all and reaching target without hypoglycemia).

        -  To compare the frequency of occurrence and diurnal distribution of hypoglycemia by
           category of hypoglycemia (documented symptomatic, asymptomatic, nocturnal, severe,
           probable and relative).

        -  To assess the safety and tolerability of insulin glargine (U300).

        -  To assess the development of anti-insulin glargine antibodies (AIA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total maximum study duration per patient will be 29 weeks that will consist of a 2-week
      screening period, 26-week treatment period, and a 2-day post-treatment safety follow-up
      period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with at least one hypoglycemia</measure>
    <time_frame>Baseline, up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with at least one nocturnal hypoglycemia</measure>
    <time_frame>Baseline, up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with HbA1c &lt;7.0%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with HbA1c ≤6.5%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with Fasting Plasma Glucose (FPG) &lt;100 mg/dL (5.6 mmol/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with FPG ≤120 mg/dL (6.7 mmol/L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients requiring rescue therapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 8-point Self-monitored Plasma Glucose (SMPG) profiles</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mean 24-hour plasma glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in variability of plasma glucose profile</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily basal insulin dose</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Toujeo - insulin glargine (U300)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus - insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine (U300)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Toujeo - insulin glargine (U300)</arm_group_label>
    <other_name>HOE901; Toujeo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Lantus - insulin glargine</arm_group_label>
    <other_name>HOE901; Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-insulin antihyperglycemic drugs</intervention_name>
    <description>Pharmaceutical form: capsule/tablet
Route of administration: oral</description>
    <arm_group_label>Toujeo - insulin glargine (U300)</arm_group_label>
    <arm_group_label>Lantus - insulin glargine</arm_group_label>
    <other_name>Non-insulin antihyperglycemic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Adult patients with type 2 diabetes mellitus inadequately controlled with non-insulin
             antihyperglycemic drug(s).

          -  Signed written informed consent.

        Exclusion criteria:

          -  Age &lt; legal age of adulthood.

          -  HbA1c &lt;7.0% (&lt;53 mmol/mol) or &gt;11% (&gt;97 mmol/mol) (at screening).

          -  History of type 2 diabetes mellitus for less than 1 year before screening.

          -  Less than 6 months before screening with non-insulin antihyperglycemic treatment.

          -  Change in dose of non-insulin antihyperglycemic treatment in the last 3 month before
             screening.

          -  Initiation of new glucose-lowering medications and/or weight loss drug in the last 3
             months before screening visit and/or initiation of glucagon like peptide-1(GLP-1)
             receptor agonist in the last 6 months before screening visit.

          -  Patients receiving only non-insulin antihyperglycemic drugs not approved for
             combination with insulin according to local labeling (Note: non-insulin
             antihyperglycemic drugs not approved for combination with insulin are to be
             discontinued at randomization).

          -  Current or previous insulin use except for a maximum of 10 consecutive days (eg,
             acute illness, surgery) during the last one year prior to screening.

          -  Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic
             ketoacidosis in the last 6 months before screening visit.

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 1560016</name>
      <address>
        <city>Changzhou</city>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560002</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560031</name>
      <address>
        <city>Tangshan</city>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560044</name>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100003</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100005</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100004</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100006</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100007</name>
      <address>
        <city>Seoul</city>
        <zip>138-878</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100008</name>
      <address>
        <city>Seoul</city>
        <zip>139-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>August 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
